ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
SchizophreniaBipolar I Disorder
Interventions
DEVICE

ERG assessment (RSPA)

Processing and analysis of retinal signals

Trial Locations (19)

3004

Albert Road Clinic, Melbourne

3168

Monash Medical Centre, Clayton

3220

Barwon Health University Hospital, Geelong

10314

Richmond Behavioral Associates, Staten Island

11004

The Zucker Hillside Hospital, Glen Oaks

14642

University of Rochester Medical Center, Rochester

33016

Segal Trials Miami Lakes Medical Research, Miami Lakes

33319

Segal trials West Broward Outpatient Site, Lauderhill

75062

University Hills Clinical Research, Irving

90502

Collaborative Neuroscience Research LLC, Torrance

91945

Synergy San Diego, Lemon Grove

92845

Collaborative Neuroscience Research LLC, Garden Grove

02478

McLean Hospital, Belmont

08854

Rutgers University Behavioral HealthCare, Piscataway

K7L 3N6

Queen's University, Kingston

M6J 1H4

Centre for Addiction and Mental Health (CAMH), Toronto

H1N 3M5

Institut Universitaire en Santé Mentale de Montréal, Montreal

H4H 1R3

Douglas Mental Health University Institute, Montreal

G5Y 4T8

CISSS-CA Hôpital de Saint-Georges, Saint-Georges

All Listed Sponsors
lead

diaMentis Inc.

INDUSTRY

NCT03788811 - ERG Components in Schizophrenia and Bipolar Disorder Type I | Biotech Hunter | Biotech Hunter